PD98059

Name: PD98059
Brand: Selleck Chemicals
SKU: S1177
Rating: 5 (198 reviews)

For research use only. Not for use in humans.

Catalog No.S1177

198 publications

Molecular Weight(MW): 267.28

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Selleck's PD98059 has been cited by 198 publications

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Cell, 2019, 35(1):17-32

PubMed: 30645973 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):798-815.e5

PubMed: 31031016 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):329-344

PubMed: 28089908 ( click the link to review the publication )

Cancer Cell, 2017, 32(6):840-855

PubMed: 29232556 ( click the link to review the publication )

Nature, 2016, 10.1038/nature19347

PubMed: 27580028 ( click the link to review the publication )

Cancer Cell, 2014, 26(5):754-69

PubMed: 25446900 ( click the link to review the publication )

Cancer Cell, 2014, 26(5):754-69

PubMed: 25446900 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 200(5):617-627

PubMed: 30817168 ( click the link to review the publication )

Nat Commun, 2019, 10(1-:1128

PubMed: 30850660 ( click the link to review the publication )

EMBO J, 2019, 38(12)

PubMed: 31068361 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-19-1555

PubMed: 31744816 ( click the link to review the publication )

BMC Med, 2019, 17(1):42

PubMed: 30782145 ( click the link to review the publication )

Oncogene, 2019, 38(49):7433-7446

PubMed: 31427736 ( click the link to review the publication )

EBioMedicine, 2019, 42:326-339

PubMed: 30879923 ( click the link to review the publication )

Cancer Lett, 2019, 10.1016/j.canlet.2019.07.016

PubMed: 31352079 ( click the link to review the publication )

Emerg Microbes Infect, 2019, 8(1):934-945

PubMed: 31237474 ( click the link to review the publication )

J Clin Med, 2019, 8(6)

PubMed: 31238539 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):75

PubMed: 31307477 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(22):10610-10625

PubMed: 31785145 ( click the link to review the publication )

Cell Prolif, 2019, 52(3):e12575

PubMed: 30838710 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):80

PubMed: 30849996 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):350

PubMed: 31775870 ( click the link to review the publication )
Pharmacol Res, 2019, 143:73-85

PubMed: 30862605 ( click the link to review the publication )

J Cell Physiol, 2019, 234(6):8846-8861

PubMed: 30317597 ( click the link to review the publication )

Front Oncol, 2019, 9:1244

PubMed: 31799197 ( click the link to review the publication )

J Biol Chem, 2019, 294(18):7221-7230

PubMed: 30846565 ( click the link to review the publication )

Inflammopharmacology, 2019, 27(3):561-571

PubMed: 30251233 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:2653-2661

PubMed: 31114328 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 362:59-66

PubMed: 30352208 ( click the link to review the publication )

Cell Signal, 2019, 54:17-26

PubMed: 30471465 ( click the link to review the publication )

Biomed Pharmacother, 2019, 116:109032

PubMed: 31163381 ( click the link to review the publication )

Life Sci, 2019, 235:116863

PubMed: 31513817 ( click the link to review the publication )

J Cell Biochem, 2019, 120(8):12500-12507

PubMed: 30834595 ( click the link to review the publication )

Life Sci, 2019, 229:1-12

PubMed: 30910647 ( click the link to review the publication )

Exp Cell Res, 2019, 379(1):65-72

PubMed: 30898547 ( click the link to review the publication )

J Tissue Eng Regen Med, 2019, 13(4):625-636

PubMed: 30770650 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(2):411-427

PubMed: 30483898 ( click the link to review the publication )

Molecules, 2019, 24(6)

PubMed: 30901941 ( click the link to review the publication )

Molecules, 2019, 24(6)

PubMed: 30889805 ( click the link to review the publication )

Free Radic Res, 2019, 53(3):348-358

PubMed: 30773942 ( click the link to review the publication )

Biosci Rep, 2019, 39(11)

PubMed: 31548362 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2019, 10.1016/j

PubMed: 31422034 ( click the link to review the publication )

Environ Toxicol, 2019, 34(6):679-688

PubMed: 30801954 ( click the link to review the publication )

Am J Reprod Immunol, 2019, 81(1):e13073

PubMed: 30461130 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.11.110

PubMed: 31761326 ( click the link to review the publication )
Lipids Health Dis, 2019, 18(1):71

PubMed: 30909920 ( click the link to review the publication )

Cell Reprogram, 2019, 21(5):238-248

PubMed: 31369321 ( click the link to review the publication )

Commun Biol, 2019, 2:359

PubMed: 31602408 ( click the link to review the publication )

Am J Chin Med, 2019, 913-931

PubMed: 31096773 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Oncogene, 2018, 37(24):3275-3289

PubMed: 29551771 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):115

PubMed: 29866191 ( click the link to review the publication )

Cell Death Dis, 2018, 9(12):1140

PubMed: 30442927 ( click the link to review the publication )

Br J Cancer, 2018, 119(9):1094-1105

PubMed: 30401978 ( click the link to review the publication )

Oxid Med Cell Longev, 2018, 2018:4572893

PubMed: 30538801 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(1):57-66

PubMed: 28964848 ( click the link to review the publication )

J Virol, 2018, 92(8)

PubMed: 29386287 ( click the link to review the publication )

Sci Rep, 2018, 8(1-:10070

PubMed: 29968778 ( click the link to review the publication )

Inflammopharmacology, 2018, 10.1007/s10787-018-0492-y

PubMed: 29748880 ( click the link to review the publication )

Biomed Pharmacother, 2018, 105:320-325

PubMed: 29864620 ( click the link to review the publication )

Tissue Eng Part A, 2018, 24(5-6):502-515

PubMed: 28602124 ( click the link to review the publication )

J Cell Biochem, 2018, 119(1):300-313

PubMed: 28569433 ( click the link to review the publication )

J Agric Food Chem, 2018, 66(41):10721-10728

PubMed: 30257559 ( click the link to review the publication )

J Agric Food Chem, 2018, 66(31):8307-8318

PubMed: 29961319 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(2):109-117

PubMed: 25588050 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2018, 144(8):1487-1501

PubMed: 29858683 ( click the link to review the publication )

Toxicology, 2018, 408:62-69

PubMed: 29981841 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):29-38

PubMed: 29749533 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )
Neurochem Res, 2018, 43(10-:1963-1977

PubMed: 30136162 ( click the link to review the publication )

PLoS One, 2018, 13(9):e0203402

PubMed: 30192802 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0197422

PubMed: 29763460 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 496(4):1291-1295

PubMed: 29412164 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(3):155-165

PubMed: 29441602 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):7443-7449

PubMed: 29731895 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):8442-8446

PubMed: 29805580 ( click the link to review the publication )

In Vivo, 2018, 32(3):549-554

PubMed: 29695559 ( click the link to review the publication )

In Vivo, 2018, 32(6):1361-1368

PubMed: 30348689 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Commun, 2017, 8:15776

PubMed: 28585539 ( click the link to review the publication )

Anesthesiology, 2017, 126(5):868-881

PubMed: 28121635 ( click the link to review the publication )

Cancer Lett, 2017, 395:31-44

PubMed: 28268166 ( click the link to review the publication )

Cancer Lett, 2017, 401:1-10

PubMed: 28483515 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 41(5):1957-1969

PubMed: 28391263 ( click the link to review the publication )

Mol Cell Proteomics, 2017, 16(9):1694-1704

PubMed: 28674151 ( click the link to review the publication )

Cell Prolif, 2017, 50(1)

PubMed: 27790820 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2017, 171:318-327

PubMed: 28529129 ( click the link to review the publication )

Immunol Cell Biol, 2017, 95(10):943-952

PubMed: 28878297 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:1037-1044

PubMed: 28292012 ( click the link to review the publication )

Biomed Pharmacother, 2017, 87:332-341

PubMed: 28064106 ( click the link to review the publication )

Exp Cell Res, 2017, 360(2):281-291

PubMed: 28919123 ( click the link to review the publication )

Chem Biol Interact, 2017, 270:1-8

PubMed: 28390675 ( click the link to review the publication )

Am J Transl Res, 2017, 9(6):2878-2890

PubMed: 28670376 ( click the link to review the publication )
Dev Comp Immunol, 2017, 76:392-402

PubMed: 28713009 ( click the link to review the publication )

Oncol Rep, 2017, 38(1):591-597

PubMed: 28560404 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1036-1044

PubMed: 28000898 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:627-643

PubMed: 28223821 ( click the link to review the publication )

DNA Cell Biol, 2017, 36(11):1029-1038

PubMed: 28945461 ( click the link to review the publication )

Exp Dermatol, 2017, 26(5):409-415

PubMed: 27762043 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 492(2):206-211

PubMed: 28821432 ( click the link to review the publication )

Food Nutr Res, 2017, 61(1):1368321

PubMed: 28970779 ( click the link to review the publication )

Microb Pathog, 2017, 10.1016/j.micpath

PubMed: 28131949 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2017, 2017:5985703

PubMed: 28167972 ( click the link to review the publication )

Mol Med Rep, 2017, 16(2):1445-1450

PubMed: 29067463 ( click the link to review the publication )

Mol Med Rep, 2017, 16(2):1417-1424

PubMed: 28627644 ( click the link to review the publication )

Poult Sci, 2017, 96(9):3043-3051

PubMed: 28431078 ( click the link to review the publication )

Oncotarget, 2017, 8(15):24237-24249

PubMed: 27458161 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(4):524-34

PubMed: 26166769 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(5):640-50

PubMed: 27593484 ( click the link to review the publication )

Br J Dermatol, 2016, 175(6):1221-1231

PubMed: 27145925 ( click the link to review the publication )

Mol Oncol, 2016, 10(6):775-88

PubMed: 26842883 ( click the link to review the publication )

Neoplasia, 2016, 18(7):425-35

PubMed: 27435925 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:2572175

PubMed: 26962394 ( click the link to review the publication )

J Ethnopharmacol, 2016, 193:293-302

PubMed: 27553977 ( click the link to review the publication )

Prostate, 2016, 76(3):273-85

PubMed: 26499308 ( click the link to review the publication )
Exp Cell Res, 2016, 345(1):82-92

PubMed: 27237094 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 80:132-142

PubMed: 27702651 ( click the link to review the publication )

Cell Immunol, 2016, 310:63-70

PubMed: 27687530 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Int J Mol Med, 2016, 38(4):1125-34

PubMed: 27599586 ( click the link to review the publication )

Neurochem Res, 2016, 41(7):1635-44

PubMed: 26961889 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 474(2):330-7

PubMed: 27107695 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Pharm Biol, 2016, 54(10):2220-35

PubMed: 27049854 ( click the link to review the publication )

Sci Rep, 2016, 6:30121

PubMed: 27444207 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43442-43460

PubMed: 27259276 ( click the link to review the publication )

Toxicol Res (Camb), 2016, 5(6):1573-1584

PubMed: 30090458 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10257-67

PubMed: 26831668 ( click the link to review the publication )

Tumour Biol, 2016, 37(3):3727-38

PubMed: 26468015 ( click the link to review the publication )

Pflugers Arch, 2016, 468(11-12):2041-2051

PubMed: 27592222 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms9390

PubMed: 26399630 ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(9):2660-72

PubMed: 26609474 ( click the link to review the publication )

J Transl Med, 2015, 13(1):42

PubMed: 25638174 ( click the link to review the publication )

Cytokine, 2015, 17:139-144

PubMed: ( click the link to review the publication )

Cytokine, 2015, 71(2):139-44

PubMed: 25461391 ( click the link to review the publication )

J Orthop Res, 2015, 10.1002/jor.22830

PubMed: 25731708 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 585:10-16

PubMed: 26363213 ( click the link to review the publication )
Toxicol In Vitro, 2015, 30(1 Pt B):521-8

PubMed: 26363202 ( click the link to review the publication )

Neurochem Res, 2015, 40(8):1609-19

PubMed: 26088686 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 463(4):612-7

PubMed: 26043686 ( click the link to review the publication )

Exp Biol Med, 2015, 10.1177/1535370215576312

PubMed: 25767191 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Acta Biochim Biophys Sin, 2015, 47(7), 1–9

PubMed: 26071572 ( click the link to review the publication )

Cell Biochem Funct, 2015, 33(3):134-42

PubMed: 25753185 ( click the link to review the publication )

Tissue Cell, 2015, 47(3):301-10

PubMed: 25958163 ( click the link to review the publication )

Growth Factors, 2015, 33(5-6):356-65

PubMed: 26607681 ( click the link to review the publication )

Genet Mol Res, 2015, 14(4):18325-33

PubMed: 26782480 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1187

PubMed: 24743742 ( click the link to review the publication )

FASEB J, 2014, 10.1096/fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-37

PubMed: 24482380 ( click the link to review the publication )

Carcinogenesis, 2014, 35(4):795-806

PubMed: 24265293 ( click the link to review the publication )

Cell Microbiol, 2014, 16(9):1441-55

PubMed: 24779413 ( click the link to review the publication )

Biomed Pharmacother, 2014, 68(8):1037-43

PubMed: 25312822 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Toxicol Lett, 2014, 226(1):81-9

PubMed: 24495410 ( click the link to review the publication )

Oncol Rep, 2014, 32(6):2777-88

PubMed: 25335112 ( click the link to review the publication )

J Periodontal Res, 2014, 10.1111/jre.12193

PubMed: 24854880 ( click the link to review the publication )

PLoS One, 2014, 9(3):e85705

PubMed: 24633332 ( click the link to review the publication )

PLoS One, 2014, 9(1):e87311

PubMed: 24489893 ( click the link to review the publication )

PLoS One, 2014, 9(5):e94753

PubMed: 24787138 ( click the link to review the publication )
Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):167-72

PubMed: 24582558 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2014, 64(2):180-90

PubMed: 24705173 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2014, Zhang JL

PubMed: ( click the link to review the publication )

Oncol Lett, 2014, 8(4):1739-1744

PubMed: 25202402 ( click the link to review the publication )

Regul Pept, 2014, 194-195:41-8

PubMed: 25450576 ( click the link to review the publication )

Hepatology, 2013, 59(4):1262-72

PubMed: 23929627 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

J Thromb Haemost, 2013, 12(3):395-408

PubMed: 24354620 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2013, 144PA:223-227

PubMed: 24514755 ( click the link to review the publication )

Mol Cell Endocrinol, 2013, 375(1-2):89-96

PubMed: 23707617 ( click the link to review the publication )

Cell Signal, 2013, 26(3):512-20

PubMed: 24308969 ( click the link to review the publication )

Microbes Infect, 2013, 15(2):105-14

PubMed: 23164610 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82610

PubMed: 24340049 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70732

PubMed: 23967093 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56735

PubMed: 23468877 ( click the link to review the publication )

PLoS One, 2013, 8(12):e85032

PubMed: 24376862 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63890

PubMed: 23667687 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 429(3-4):156-62

PubMed: 23142594 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Genetic Syndromes & Gene Therapy, 2013, 4:6

PubMed: ( click the link to review the publication )

J Natl Cancer Inst, 2012, 104(21):1673-9

PubMed: 22997239 ( click the link to review the publication )
J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

Microbiol Immunol, 2012, 56(11):782-8

PubMed: 22938101 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Atheroscler, 2011, 218(2):486-92

PubMed: 21782178 ( click the link to review the publication )

Int J Mol Med, 2011, 28(1):115-9

PubMed: 21455558 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Features

Does not inhibit c-Raf phosphorylated MEK1.

Targets

MEK1 ^[1]
(Cell-free assay)

2 μM

In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. ^[1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. ^[2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. ^[3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
H1355	M2j6UGZ2dmO2aX;uJGF{e2G7	NWfRU\|RwOjVizszN	MmfmNUBp		M2jmZ4JtfW62czD0bIUhSlujXWCtbY5lfWOnZDDpcoNz\WG\|ZTDpckBxcG:\|cHjvMWNpczFiYX7kJJBpd3OyaH:tSXJMKGW6cILld5Nqd25?	MofKNlU4PjlzOEG=
MCF-7	NXnrfopJTnWwY4Tpc44hSXO\|YYm=	MkXkNVAh\|ryP	MUKxJIg>		MYnpcohq[mm2czDJUE0yQC2nbnjhcoNm\CClZXzsJI1q\3KjdHnvci=>	NF;JXFMzPTd{N{CxNS=>
HepG2	NELrNFJHfW6ldHnvckBCe3OjeR?=	M4\XcVExKM7:TR?=	NGrOSng2KGh?		M3rnXIJtd2OtczDwbI9{eGixconsZZRm\CCPQWDLd{BqdmS3Y3XkJIJ6KGW6b3flco92eyCWR1[t{tIy	MlyxNlU2PjB2OEi=
HepG2	MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\BWGhxOjBizszN	MViyOEBp		MonGd5VxeHKnc4Pld{BVT0ZvzsKxMYlv\HWlZXSgZ4VtdCCycn;sbYZmemG2aX;uJIFv\CCrbo\hd4lwdg>?	NHzheJIzPTV4MES4PC=>
MDA-MB-231	NW\EUXZ{TnWwY4Tpc44hSXO\|YYm=	MVWyOUDPxE1?	MUSyMVMhcA>?		Mofw[IVkemWjc3XzJJAuTVKNMT:yJIFv\CCVMUCwRVQh\XiycnXzd4lwdg>?	NGOx[lAzPTV3NUi3OS=>
SW480	M2LMdWZ2dmO2aX;uJGF{e2G7	NGfHOVUzOMLizszN	NX\SeFJLOcLiaB?=		M1rFcJJm\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gRXRHOyCycn;0[Ylv	NF75XVQzPTR2N{ixOi=>
HCT-15	MUnGeY5kfGmxbjDBd5NigQ>?		MXSxJIg>		MnXaZZR1\W63YYTld{BRT0V{LXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb:Kh	NX\kPFBwOjV2M{G0NlU>
HCT-15	NWDlZ3F[SXCxcITvd4l{KEG\|c3H5		NE\IVIgyKGh?		MnjiZYJwdGm\|aHXzJJRp\SCycn;0[YN1cX[nIHXm[oVkfHNib3[gVGdGOsLiYXfhbY5{fCCldYLjeY1qdi2rbnT1Z4VlKGGyb4D0c5Nqew>?	M37SRlI2PDNzNEK1
786-O	Ml;nRZBweHSxc3nzJGF{e2G7	NGHZcHg2OMLizszN	MkHVNlQhcA>?		NHrrXnhxd3SnboTpZZRme8LidHjlJJBzdy2jcH;weI91cWNiZX\m[YN1eyCxZjDORy=>	M1\BWlI1PTB6NEe2
A498	NYTTPHVvSXCxcITvd4l{KEG\|c3H5	M4LnN\|UxyqEQvF2=	NHjMW4wzPCCq		M2OwT5BwfGWwdHnheIV{yqC2aHWgdJJwNWGyb4D0c5Rq[yCnZn\lZ5R{KG:oIF7D	MlfGNlQ2ODh2N{[=
NHBE	M1j0cGZ2dmO2aX;uJGF{e2G7	M1XL[lIwOjBizszN	NYLDO25OOiCq		NGHDW\|VifHSnboXheIV{KEmOLUOzJJN1cW23bHH0[YQhS1iFTEivTWwuQCC\|ZXPy[ZRqd25?	NHHmdWMzPDR5OUWyOi=>
A375	M{G3WmNmdGxiSX72ZZNqd25iQYPzZZk>	NF7OSZQyOOLCk{KwJOK2VQ>?	M4TQOVI1KGh?		NIHrTnlz\WS3Y3XzJI1mdGGwb33hJINmdGxiaX72ZZNqd25?	NX;C[G5MOjR2Nk[wN\|Y>
HBMEC	MV7GeY5kfGmxbjDBd5NigQ>?	M2nCTlExKM7:TR?=	NYHkNIhpOSCq		MlLNZoxw[2u\|IG\FS2YucW6mdXPl[EBGeGiDMjDlfJBz\XO\|aX;u	MVOyOFQ2QDl6Mh?=
HPAEpiCs	NInmbI9HfW6ldHnvckBCe3OjeR?=	NXnocWNuOzBizszN	NGnhepUyKGh?		M3HrO4lvcGmkaYTzJHRPTi4QsTDzeIlufWyjdHXkJJA1Oi:yNESgUWFRUyCyaH;zdIhwenmuYYTpc44>	MoXCNlQ1PDF6N{C=
BeWo	NEXnU4JHfW6ldHnvckBCe3OjeR?=	Mk\CNVDDqM7:TR?=	NELZOJczKGh?		MVjpcohq[mm2czDFVmsyNzJ?	NVHSO5FrOjR2M{O4OFY>
PC3	NIrGSpJCeG:ydH;zbZMhSXO\|YYm=	NVHmPGdVPTBizszN	M3[3NFAvPSCq		NH3YTYJqdmirYnn0d{BOUFlvNES5MYlv\HWlZXSgZZBweHSxc3nzxsA>	MV[yOFQzPDh6OR?=
HGC-27	NIr2WGVCeG:ydH;zbZMhSXO\|YYm=	MnXBNUDDvU1?	MVKxJIg>		NWLlU2Vxe3WycILld5NmeyCUQVSwNFEheGy3czDNT{0zOjB4LXnu[JVk\WRiY3XscEB3cWGkaXzpeJkhdG:\|cx?=	M1LLcFI1PDF4M{S5
MCF-7	NFfPcGtHfW6ldHnvckBCe3OjeR?=	MmfrNVDDqM7:TR?=	Mlz5NVAwOzBibXnu		MnS5doVlfWOnczD0bIUhXVSSLXTldIVv\GWwdDDFVmsheGixc4Doc5J6dGG2aX;u	M2raWVI1OzlyOEG5
HUVECs	MXPGeY5kfGmxbjDBd5NigQ>?	MXKxNOKh\|ryP	NXL4cJQ{OSCq		NIf2TmNqdmirYnn0d{B1cGViSFTMJJJm\HWlZXSgR29ZNTJiZYjwdoV{e2mxbjDhcoQhWEeLLUKgdoVt\WG\|ZR?=	M{jTcVI1Ozh3MUC5
HeLa	NHfIdI1HfW6ldHnvckBCe3OjeR?=	M2DPcFUxKM7:TR?=	NIH1d3ExNjViaB?=		M2HmZoJtd2OtczDUVnguOSCwdXPs[YFzKG2rZ4LheIlwdiCjbnSgWHhPUVBiZH;3ck1z\We3bHH0bY9v	M161U\|I1Ozd4OEK3
HL-60	M1jlVGZ2dmO2aX;uJGF{e2G7	M1TpWlExNzJyIN88US=>	NVG0V\|JHOSCq		M3TQR4lvcGmkaYTzJJRp\cLiTj6gZ4hqdmWwc3nz[Zh1emGldNMgbY5lfWOnZDDkbYZn\XKnboTpZZRqd25iaX70c{BoemGwdXzvZ5l1\XN?	MV:yOFM2PzB{MB?=
HL-60	NXvlXpRWTnWwY4Tpc44hSXO\|YYm=	MXeyJOK2VQ>?	NIn0eVAyPiCq	MXjEUXNQ	MWLpcohq[mm2czD0bIUh[XO\|b3PpZZRqd25ib3[gdHM3OjFiUnHmMVEh[W6mIF7GRXRkOyxiYX7kJJRp\SCUQT3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDueYNt\WG{IF7GRXRkOw>?	M4XIXVI1OzNyME[4
HEK 293	NUTKUJlETnWwY4Tpc44hSXO\|YYm=	MlPHNVAh\|ryP	MnXSOUBp	M3PNNmROW09?	NHLFTHJqdmirYnn0d{BYdnRvaX7keYNm\CEQsj3jZZRmdmmwL2TDSlQh[WO2aY\peJkh[W6mIH71Z4xm[XJizsKtZ4F1\W6rbjDhZ4N2dXWuYYTpc44>	M{i1elI1OzJ2M{[2
HEK 293	NWnKUFE3TnWwY4Tpc44hSXO\|YYm=	MXWxNEDPxE1?	NEj2PIY2KGh?	M1nQeGROW09?	NV7zPIsye3WycILld5NmeyC2aHWgR3JVKGGldHn2bZR6	NXnHTI52OjR\|MkSzOlY>
SW480	MkDQSpVv[3Srb36gRZN{[Xl?	NGf5T4UyOCEQvF2=	M4PZcVIxKGh?	MV3EUXNQ	NUfNXm9Ze3WycILld5NmeyC2aHWgR3JVKGGldHn2bZR6	NFfpU2ozPDN{NEO2Oi=>
HCSMCs	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYKxNEDPxE1?	M1rUUVI1KGh?		NITMPVRjdG:la4OgSmFDWDRvaX7keYNm\CCKQ1HTUWMheHKxbHnm[ZJifGmxbh?=	Mmn0NlQ{OTJ\|OEG=
PANC-1	MWfGeY5kfGmxbjDBd5NigQ>?	NEPPfpgzOCEQvF2=	NYD4VYxJPDhiaB?=		Mof1bY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[g{rQ3TCCrbjDy[ZNxd26\|ZTD0c{B1cGViUGDBVu61yqCjZ3;ubZN1yqB?	NGHLeZczPDJ7NEGzNy=>
A549	M{LuR2Z2dmO2aX;uJGF{e2G7	MnraN\|Ah\|ryP	NXH4dpJGOC53IHi=	NEXkT3dFVVOR	NGHCSWxqdmirYnn0d{B1cGVidHjyc41jcW5vaX7keYNm\CCLTD24M2NZS0x6LVz1Z{Bi[3Srdnn0fS=>	M1zUXFI1Ojd5Nkm2
A549	MkHVSpVv[3Srb36gRZN{[Xl?	NI\sPXU{OCEQvF2=	MlHwNE42KGh?	NFfhUWVFVVOR	NFjJ[HVqdmirYnn0d{B1cHKxbXLpck1qdmS3Y3XkJGMwTUKSzsKgWIhzOjN3wrDwbI9{eGixconsZZRqd25?	NWDGXVBWOjR{N{e2PVY>
MC-3	NFjaPGpCeG:ydH;zbZMhSXO\|YYm=	M{j3UlExKM7:TR?=	MYKyOEBp		MXfwc5RmdnSrYYTl[EBOTVOFLXnu[JVk\WRiYYDvdJRwe2m\|IHnuJEBk\Wyucx?=	MoHWNlQzPzB3MkO=
Raji	NV;1V2RUTnWwY4Tpc44hSXO\|YYm=	MlniNVAh\|ryP	NH22[4wyKGh?		MV7icI9kc3NiaIPCRWZHKGmwZIXj[YQhTXKtMT:yJJBpd3OyaH;yfYxifGmxbh?=	NISy[4gzPDJ4OU[zNC=>
Raji	M{TnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYixNEDPxE1?	MXWxJIg>		MmK4bY5pcWKrdIOgeIhmKGKjc3HsJI9zKGi\|QlHGSk1{fGmvdXzheIVlKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5	MXqyOFI3QTZ\|MB?=
HT29	MkfFSpVv[3Srb36gRZN{[Xl?	MXOxNEDPxE1?	M3WxZlIhcA>?		NVLv[HVkcW6qaXLpeJMhd2ZiSlHLNkwhTVKNMT:yJIFv\CCVVFHUN{BxcG:\|cHjvdplt[XSrb36=	NYDyfJBYOjR{NkWyPVM>
HepG2	NUHGUmp1SXCxcITvd4l{KEG\|c3H5	M1PzTVIxKM7:TR?=	MXqyOEBp		MXnpcohq[mm2czDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGGwZDDlcohidmOnczDWRlEucW6mdXPl[EBieG:ydH;zbZM>	Ml24NlQzPDd7MEm=
HepG2	MU\GeY5kfGmxbjDBd5NigQ>?	NGfiTJAzOCEQvF2=	NVm4W29sOiCq		NHu3SmdmdmijbnPld{BXSjFvaX7keYNm\CCIT2jPN4EhfHKjboPjdolxfGmxbnHsJIFkfGm4aYT5	NFTO[Y0zPDJ2N{mwPS=>
TE4	M2i1NWZ2dmO2aX;uJGF{e2G7	M{\pdlIxNzVyL{GwNEDPxE1?	MXy0PEBp	MmPYSG1UVw>?	NYjCVG9HcW6qaXLpeJMheC2HcnugZY5lKHexcoTtZY5vcW5iZH;3cpJm\3WuYYTl[EBxNUGtdDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M2\1fFI1OjR2MEKz
TE1	Ml7GSpVv[3Srb36gRZN{[Xl?	M2fSZlIxNzVyL{GwNEDPxE1?	M4fKSFQ5KGh?	NH76NodFVVOR	M1XUdolvcGmkaYTzJJAuTXKtIHHu[EB4d3K2bXHucolvKGSxd37y[Yd2dGG2ZXSgdE1Cc3RiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NFjES5gzPDJ2NECyNy=>
KYSE30	NWTyZY8{TnWwY4Tpc44hSXO\|YYm=	NF7k[3MzOC93MD:xNFAh\|ryP	Mo\UOFghcA>?	MWTEUXNQ	MYXpcohq[mm2czDwMWVzcyCjbnSge49zfG2jbn7pckBld3ewcnXneYxifGWmIICtRYt1KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M3LJR\|I1OjR2MEKz
TE1	NX22OVlvTnWwY4Tpc44hSXO\|YYm=	NYftZ2J{PTBizszN	Mm\jOFghcA>?	NGDCV3lFVVOR	MmrEeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl?	NXzDTXBuOjR{NESwNlM>
TE3	MorQSpVv[3Srb36gRZN{[Xl?	MojGOVAh\|ryP	MV20PEBp	M1vLUmROW09?	NX[2OY8zfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO\|IFm=	MkKwNlQzPDRyMkO=
TE4	M1vJTWZ2dmO2aX;uJGF{e2G7	Moi1OVAh\|ryP	NHXWR2M1QCCq	Mm[ySG1UVw>?	NInqUpl2eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCKTFGgZ4xie3NiSR?=	MWeyOFI1PDB{Mx?=
TE5	Mo\2SpVv[3Srb36gRZN{[Xl?	MoPWOVAh\|ryP	NGS2c\|Q1QCCq	MX;EUXNQ	MUf1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>?	MmH3NlQzPDRyMkO=
KYSE30	M2TkNmZ2dmO2aX;uJGF{e2G7	MnPIOVAh\|ryP	NHjPUFM1QCCq	MmnrSG1UVw>?	NUHKdpJFfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO\|IFm=	MWWyOFI1PDB{Mx?=
MKN7	NVW2OlM1TnWwY4Tpc44hSXO\|YYm=	M{PUfFUxKM7:TR?=	NXG1dJU5PDhiaB?=	Mof4SG1UVw>?	MVzpcoNz\WG\|ZYOg[ZhxemW\|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW\|	M2qzPFI1OjR2MEKz
OE19	NIGzPZFHfW6ldHnvckBCe3OjeR?=	MUO1NEDPxE1?	MmPNOFghcA>?	M13rRWROW09?	M{fHS4lv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO=	M2HTR\|I1OjR2MEKz
KATOIII	M{e3eGZ2dmO2aX;uJGF{e2G7	M3\mUVUxKM7:TR?=	NEXWe2Y1QCCq	NGfre\|hFVVOR	NFuzV4tqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz	NGKye2gzPDJ2NECyNy=>
NCI-N87	NVrWdIo1TnWwY4Tpc44hSXO\|YYm=	NYCzcopoPTBizszN	NEHYeWk1QCCq	NEPTbopFVVOR	M1TCRolv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO=	NFfLWIEzPDJ2NECyNy=>
NUGC3	MYjGeY5kfGmxbjDBd5NigQ>?	NYXtUYNtPTBizszN	NW\BfGVHPDhiaB?=	Mki4SG1UVw>?	NWHRR4QzcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=>	NXKxPWZVOjR{NESwNlM>
NUGC2	MmfSSpVv[3Srb36gRZN{[Xl?	NF7QWFA2OCEQvF2=	MnTKOFghcA>?	MmHaSG1UVw>?	NGjCeZdqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz	NID1coYzPDJ2NECyNy=>
SGC-7901	NVf3dpFmSXCxcITvd4l{KEG\|c3H5	M3rBR\|IxKM7:TR?=	MV[yOEBp		M2nBc4lvcGmkaYTzJGNRNW2nZHnheIVlKGGyb4D0c5Nqew>?	NFPLTVYzPDJ2MUO1NS=>
MG-63	MYXGeY5kfGmxbjDBd5NigQ>?	M3n0Z\|IxKM7:TR?=	NHi0W4UxNjViaB?=		MYPicI9kc3NidHjlJGNJNWmwZIXj[YQheGixc4Doc5J6dGG2ZXSgSWxMOSCycn;0[YlvKGW6cILld5Nqd25?	M1m2VVI1OjN7NkSw
ARPE-19	MWrGeY5kfGmxbjDBd5NigQ>?	NYPjc4E2OjBizszN	MYGwMlUhcA>?		MmWxbY5pcWKrdIOgRZBmdGmwLXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb{BidmRiQXv0	MWeyOFIzPzlzOB?=
CRL-2302	M1SwWWZ2dmO2aX;uJGF{e2G7	NFX0dY0zOCEQvF2=	M1;xclAvPSCq		M4nK[4lvcGmkaYTzJGFx\Wyrbj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDFdosh[W6mIFHreC=>	MViyOFIzPzlzOB?=
MCF-7	MlrjSpVv[3Srb36gRZN{[Xl?	MYKyNEDPxE1?	MlTYNUBp		MVjhZo9tcXOqZYOg[ZhxemW\|c3nvckBw\iCyaH;zdIhwenmuYYTl[EBGWktiY3:teJJm[XSvZX70JJdqfGhiY3;ubpVo[XSn	M3fFN\|I1OjF4Mki5
MCF-7	MoTPRZBweHSxc3nzJGF{e2G7	MmXDNlAh\|ryP	MXSxJIg>		NWfE[XJocW6lcnXhd4V{KGOjc4Dhd4UuQSCnbor5cYUh[WO2aY\peJk>	NGLtOYozPDJzNkK4PS=>
DLD-1	NYTadJNVTnWwY4Tpc44hSXO\|YYm=	M3yy[\|IxyqEQvF2=	MXS0PEBp		NIrsXJNz\WS3Y3XzJJRp\SCETlnQN{BmgHC{ZYPzbY9vKHC{ZT30doVifGWmIIfpeIghPS2jenGt[GM>	M1TEeFI1OjFzNUix
HT-29	MlzRSpVv[3Srb36gRZN{[Xl?	MVKyNOKh\|ryP	MWO0PEBp		NEH2e\|Rz\WS3Y3XzJJRp\SCETlnQN{BmgHC{ZYPzbY9vKHC{ZT30doVifGWmIIfpeIghPS2jenGt[GM>	Mn;CNlQzOTF3OEG=
7402	Mm\XRZBweHSxc3nzJGF{e2G7	NYDxN3dwOzBizszN	M1;hVFUh\A>?		MnrD[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=>	MofmNlQzOTF{NUO=
7721	NFPReplCeG:ydH;zbZMhSXO\|YYm=	NWHzV5llOzBizszN	MXu1JIQ>		MYHk[YNz\WG\|ZYOgZ4VtdCCycn;sbYZmemG2aX;u	Ml3DNlQzOTF{NUO=
SGC7901	NVTVdWF5SXCxcITvd4l{KEG\|c3H5	M3zNeFUxyqEQvF2=	NInYN5EzPC92OD:3NkBp	MnGzSG1UVw>?	M4nifYlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiSlHLNkB{cFKQQR?=	NIDEVJozPDF5OEK0NC=>
SMMC7721	M3S2cmZ2dmO2aX;uJGF{e2G7	Mn\2NlUwPTBizszN	NH;BfIszPCCq		NXW0bGNbe3WycILld5NmeyC2aHWg[ZhxemW\|c3nvckBw\iCyLVHreEBweiCyLVXST\|EwOsLi	NH;RVWwzPDF4OEC1Oi=>
MCF-7	M4LUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXqxNEDPxE1?	NX3mVW9pPDiq	MVfEUXNQ	M13qNpJmfmW{c3XzJGJPTi2rbnT1Z4VlKGOnbHygZ5lkdGViYYLy[ZN1	MWCyOFE3OzRyNB?=
Caco-2	NUC1TlZjTnWwY4Tpc44hSXO\|YYm=	MWm1NOKh\|ryP	M3fWXlQ5cA>?	MlnQSG1UVw>?	MYrlcohidmOnczD0bIUhdVKQQTDs[ZZmdHNib3dCpHNEVk5zQTzGXHlFOy{EoFzDWEzDqEyRWD\|CpGhKTjODLNMgXmcyPi{EoGDESVZCyqCjbnVCpGxISUyVMUdCpIdmdmW\|wrDjc{11emWjdHXkJJdqfGhiRHX4	NX\JToZ1OjRzNkG2PVU>
HAECs	NXPWS4R[TnWwY4Tpc44hSXO\|YYm=	MWixNEDPxE1?	M13JRlEhcA>?		MYdCpIF1fGWwdXH0[ZMhXE6ILd8xMZN1cW23bHH0[YQhUUODTT2xJIFv\CCYQ1HNMVEh\XiycnXzd4lwdg>?	NGfxXZozPDF\|NE[1Oy=>
Ca9-22	M2LleWZ2dmO2aX;uJGF{e2G7	NFGxUpk{KM7:TR?=	MYOxJIg>		NWrXNY92[WKxbHnzbIV{KHSqZTDhZoltcXS7IH;mJGhjWiC2bzDpcoR2[2ViSVytPEBxem:mdXP0bY9v	Mn;1NlQyOjZ3M{K=
Ca9-22	MW\GeY5kfGmxbjDBd5NigQ>?	MorYN{DPxE1?	NFHOW3QyNzJiaB?=		M1O4UZJm\HWlZYOgTIJTNWmwZIXj[YQhSVSILUKgdIhwe3Cqb4L5cIF1cW:w	MX2yOFEzPjV\|Mh?=
AGS	MVTGeY5kfGmxbjDBd5NigQ>?	M3rEclExKM7:TdMg	NEnpfmwxNjViaB?=		NI\QN2FqdmirYnn0d{B1cGVidYDy[Yd2dGG2aX;uJI9nKHSqZTDJUE05KGenbnW=	MnvTNlQyODZzNk[=
Caco-2	MWXBdI9xfG:\|aYOgRZN{[Xl?	NGfXOpkyOMLizszN	M{T3dVI1yqCq		NFziUIxl\WO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUA2NU[X	MWKyOFA6PTh4Mx?=
HCT-8	NYizT5Q1SXCxcITvd4l{KEG\|c3H5	M3LKUFExyqEQvF2=	MUOyOOKhcA>?		M4\WTYRm[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JFUuTlV?	MVqyOFA6PTh4Mx?=
A549	M4XyUGZ2dmO2aX;uJGF{e2G7	M{fIXVUxyqEQvF2=	MlPjNkBp		M1HCT4Jtd2OtczDFVmsheGixc4Doc5J6dGG2aX;uJI1m\GmjdHXkJIJ6KDFuMj3OVS=>	M1TsW\|I1ODZ5N{K3
HPMC	NETTRVBHfW6ldHnvckBCe3OjeR?=	M1LEeFExyqEQvF2=	NW\wOph2PDhiaB?=		NWLGUGRwemW4ZYLz[ZMhfGinIHPoZY5o\XNiaX6gZ4VtdCCvb4LwbI9td2e7IHnu[JVk\WRiYomgTGdRTFN?	NFL5cokzPDB2MkizPC=>
HPMC	M2P3NmFxd3C2b4Ppd{BCe3OjeR?=	M4L2NVExyqEQvF2=	MWiyOOKhcA>?		MmfJdoV3\XK\|ZYOg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY5lfWOnZDDifUBJT1CGUx?=	MWOyOFA1Ojh\|OB?=
MGC803	M4H3PWFxd3C2b4Ppd{BCe3OjeR?=	NVfH[Zg5OjEEoN88US=>	NX:5Z2lDOSCq		NF73bpZqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCLRl6t{tHDqGGwZDC15qCzNUSIVWK=	NHuyRWkzPDB{N{e1NC=>
SGC7901	M2HRNWFxd3C2b4Ppd{BCe3OjeR?=	MkLLNlDDqM7:TR?=	NHmySJIyKGh?		MkiybY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhUU[QLd8xxsBidmRiNfMAtk1FTlWU	NXHVdWl3OjRyMke3OVA>
COLO205	NGnvc49CeG:ydH;zbZMhSXO\|YYm=	Mne1NVAwOjBxNECg{txO	MkTqNlQhcA>?		NWfwZ2VpcW6mdXPld{BFVkFibHHk[IVzKG[xcn3heIlwdg>?	M{jkXVI1ODF7MUC4
G292	NHXTRpdCeG:ydH;zbZMhSXO\|YYm=	NWLGV4QyOzEEoN88US=>	M37zW\|IhcA>?		M1v1UpJme3SxcnXzJINieHOjaXPpck1qdmS3Y3XkJINmdGxiZHXheIg>	NH\weWwzPDBzMkmzNC=>
BxPC-3	M{T6dWZ2dmO2aX;uJGF{e2G7	NIL4[I0yOCEQvF5CpC=>	MYe2JIg>		M4CySolv[3KnYYPlJI1qWi1zNEOg[ZhxemW\|c3nvci=>	MkfuNlM6PzN5MUC=
HPAF-II	MnHRSpVv[3Srb36gRZN{[Xl?	M3\iUFExKM7:TdMg	Mnf1OkBp		MX\pcoNz\WG\|ZTDtbXIuOTR\|IHX4dJJme3Orb36=	MonmNlM6PzN5MUC=
HL-60	NUXLd3BmSXCxcITvd4l{KEG\|c3H5	NUfk[YpyPTEEoN88US=>	M{LBXVEhcA>?		M1OydpJme2O3ZYOgRmEyPDVibXXkbYF1\WRiYYDvdJRwe2m\|	NYnkfIh1OjN7NEi3OVE>
HepG2	MUXGeY5kfGmxbjDBd5NigQ>?	NVezRWVjPDBizszN	NVX3WnI3Pi9zMjDo		MUXpcohq[mm2czD0bIUhcW6lcnXhd4Uhd2ZicD3FVmsyKGGwZDDwMYMuUnWwIIDyc5RmcW5iZYjwdoV{e2mxbjDifUBRVA>?	NVXjRWpzOjN7NEK4OVE>
HUVECs	MmHmSpVv[3Srb36gRZN{[Xl?	M3faPFI2KM7:TR?=	M1Pud\|EhcA>?		NHXGNYdqdmO{ZXHz[UBPTi4QulKgdFY2KG63Y3zlZZIhfHKjboPsc4NifGmxbh?=	NIPpXmMzOzlyMUCwPC=>
LNCaP	NFHyflhHfW6ldHnvckBCe3OjeR?=	MVuxNEDPxE4EoB?=	MlTaNUBp		M2S1PIRm[3KnYYPld{B1cGViRVfGJJVxemWpdXzheIVlKHBvWVKtNS=>	NVf3d3RVOjN6M{izNVg>
HL60	Ml\nSpVv[3Srb36gRZN{[Xl?	MYKyNOKh\|ryP	MUK3NkBp	Mn\tSG1UVw>?	Moj3bY5pcWKrdIOg[IF{[XSrbnniMYlv\HWlZXSgR2QyOWJiZYjwdoV{e2mxbh?=	MkHUNlM5OjV3OEW=
NB4	NWr6THc2TnWwY4Tpc44hSXO\|YYm=	NYDyW5BUOTBizszNxsA>	NWH1VpI4PzJiaB?=	NHvi[45FVVOR	MWXpcohq[mm2czDkZZNifGmwaXKtbY5lfWOnZDDDSFEy[iCneIDy[ZN{cW:w	M{DVd\|I{QDJ3NUi1
EPOR/CR3	NGjDUFhHfW6ldHnvckBCe3OjeR?=	MWq1NOKh\|ryP	NGLxVVM{KGh?		Mn33doVlfWOnczDFVG8h[W6mL3;yJGlNNTNvaX7keYNm\CC2aHWgeJlzd3OrbnWgdIhwe3Cqb4L5cIF1cW:wwrC=	NVmydmRKOjN6MkC3N\|E>
HUASMCs	NYCzeYVbTnWwY4Tpc44hSXO\|YYm=	MWexNEDPxE4EoB?=	MXyyOEBp		M3fmOYRqdWmwaYPo[ZMhSW6pIFnJMYNifXOnZDDTU2NUOyCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd28EoB?=	Mly1NlM5OTZ2Nki=
HUASMCs	M3;zR2Z2dmO2aX;uJGF{e2G7	NHLUcokyOCEQvF5CpC=>	NYL5eGZsOjRiaB?=		MYHpcohq[mm2czDBcochUUlvaX7keYNm\CCHUluxM\|IheGixc4Doc5J6dGG2aX;uJIxmfmWu	NIjzSmYzOzhzNkS2PC=>
SGC7901	MWXGeY5kfGmxbjDBd5NigQ>?	MXixNEDPxE4EoB?=	MlT0NlQhcA>?		NHrzcmZqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxcG:\|cHjvdplt[XSnZDDFVmsyNzJ?	NEH1dW4zOzd7MkW4PC=>
MKN45	NYTrSlVrTnWwY4Tpc44hSXO\|YYm=	NW\WPZVbOTBizszNxsA>	NFy1WlEzPCCq		M1fjOIlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGWmIFXST\|EwOg>?	NGLYVoUzOzd7MkW4PC=>
SGC7901	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{C1VlExKM7:TdMg	NGewZ\|EzPC92OD:3NkBp		NFjM[4xqdmirYnn0d{Bk\WyuIHfyc5d1cCClbz30doVifGWmIIfpeIghTEGSVB?=	M{LxS\|I{Pzl{NUi4
MKN45	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELF[lgyOCEQvF5CpC=>	MVmyOE81QC95MjDo		M3qxdYlvcGmkaYTzJINmdGxiZ4Lve5RpKGOxLYTy[YF1\WRid3n0bEBFSVCW	MU[yN\|c6OjV6OB?=
SGC7901	MlPtRZBweHSxc3nzJGF{e2G7	NV3FN3ZGOTBizszNxsA>	NVLmSFhOOjRiaB?=		MljBbY5kemWjc3XzJJRp\SCGQWDUMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN?	NULteHZOOjN5OUK1PFg>
MKN45	NXPXbmFVSXCxcITvd4l{KEG\|c3H5	MkXPNVAh\|ryPwrC=	NEj3SY0zPCCq		NHTRN2JqdmO{ZXHz[ZMhfGinIFTBVHQucW6mdXPl[EBk\WyuIHHwc5B1d3Orcx?=	MkDsNlM4QTJ3OEi=
BxPC-3 cells	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1f4SlIxyqEQvF2=	NUS5bG1xOC53IHi=		M1jnNYlvcGmkaYTzJHZGT0ZvQT3y[Yd2dGG2ZXSgTHVXTUNiZ4Lve5RpKGGwZDD0eYJmKG[xcn3heIlwdiCrbnT1Z4VlKGK7IGDBVk0zKEGS	NHLLU40zOzd4NEC0Oi=>
NB4	MlvuRZBweHSxc3nzJGF{e2G7	NUXMepltOTBxMkCvOlAh\|ryP	NITkU2YyNjViaB?=	MWHEUXNQ	MYrk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliY3:teJJm[XSnZDD3bZRpKFCjY3zpeIF5\Wx?	NHHDdo4zOzd\|NUW0NS=>
HepG2	M3nBXGZ2dmO2aX;uJGF{e2G7	MkjmNlDDqM7:TR?=	NU\tcI8{OjRiaB?=		NH2zPVdqdmirYnn0d{B1cGViSF:tNUBxem:2ZXnuJIV5eHKnc4Ppc44h[29vdILlZZRm\CC5aYToJI1mfG[xcn3pci=>	M2LoPVI{PzB5NkC5
HUVECs	M3LaXWFxd3C2b4Ppd{BCe3OjeR?=	MUSyM\|Qh\|ryP	NWTkfGNuOjRxNEigbC=>		MXLpcoR2[2W\|IHPlcIwh\GWjdHi=	NX3nc\|duOjN5MEe1NlA>
KG-1	MXnBdI9xfG:\|aYOgRZN{[Xl?	MVeyNOKh\|ryP	M1nqZ\|EzKGh?		NInsfoNmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHMy	NH\3ZWwzOzdyNk[5NS=>
AML 1#	MXPBdI9xfG:\|aYOgRZN{[Xl?	MmLkNlDDqM7:TR?=	M4i4b\|EzKGh?		M3jTboVvcGGwY3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgV\|E>	NI\jdFYzOzdyNk[5NS=>
A2780	M3TNOWZ2dmO2aX;uJGF{e2G7	NH7rVW4zOMLizszN	NX\xcVZROSCq		NVjXcGhi[myxY3vzJGRVS0RvaX7keYNm\CCGUkWg[ZhxemW\|c3nvci=>	M1[2VFI{Pjl4OE[y

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT; PubMed: 17482134 Cancer cell ERK regulates c-Jun levels in melanoma. The indicated melanoma cell lines were treated with 50μM PD98059 (PD) or 10μM LY294002 (LY) for 12h in the absence of serum. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading. p-JNK / JNK / Cyclin D1 ; PubMed: 17482134 Cancer cell Inhibition of the MEK/ERK pathway affects c-Jun, P-JNK and cyclin D1 levels. The indicated melanoma cell lines were treated with 50μM PD98059 for 16h. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading. p-HER2 / HER2 ; PubMed: 24244023 J Immunol TE1cells were treated with wortmannin (Akt signal inhibitor), PD98059 (MAPK signal inhibitor), or lapatinib (EGFR and HER2 dual inhibitor) at the indicated doses or with DMSO as a negative control for 48 h. HER2-related signaling molecules were assessed by Western blot. MMP9 / XIAP / VEGF ; PubMed: 29695559 In Vivo SK-Hep1 cells were treated 10 μM PD98059 for 48 h. Protein levels of MMP-9, XIAP, VEGF, cyclin-D1, and pERK were evaluated with western blotting assay.	17482134 24244023 29695559

In vivo

Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. ^[5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. ^[6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. ^[7]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro MEK-inhibitory activity: Incorporation of ³²P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl₂/2 mM EGTA/10 μM [γ-³²P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research: ^[1]	- Collapse Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562 Concentrations: Dissolved in DMSO, final concentrations ~100 μM Incubation Time: 3 dyas, or 7-10 days Method: For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope. (Only for Reference)
Animal Research: ^[7]	- Collapse Animal Models: Male Sprague–Dawley rats with acute pancreatitis Formulation: Dissolved in DMSO, and diluted in saline Dosages: 10 mg/kg Administration: Injection i.v. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	14 mg/mL warmed (52.37 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD98059 SDF

Molecular Weight	267.28
Formula	C₁₆H₁₃NO₃
CAS No.	167869-21-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	COC1=C(N)C(=CC=C1)C2=CC(=O)C3=CC=CC=C3O2

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to formulate this inhibitor for i.p. injection?
Answer:
You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Pan MEK Inhibitor

U0126-EtOH : MEK1, IC50=0.07 μM; MEK2, IC50=0.06 μM.
Most Potent MEK Inhibitor

PD0325901 : MEK, IC50=0.33 nM.
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

Related MEK Products

Cobimetinib (GDC-0973) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

Features:More potent than PD0325901 or AZD6244.
PD0325901(Mirdametinib)

PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
Selumetinib (AZD6244)

Selumetinib (AZD6244) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

Features:First MEK inhibitor being tested in Phase II clinical trials.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD184352 (CI-1040)

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Features:First MEK inhibitor to begin clinical development.
Binimetinib (MEK162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.
Refametinib (RDEA119)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

PD98059